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French  health  insurance  databases  are  organized  since  2003  into  a huge  digital  data  warehouse,  the
Système  national  d’information  inter-régime  de l’assurance  maladie  (SNIIR-AM).  It covers  the  entire  French
population  (65  million  inhabitants).  In order  to facilitate  studies  on more  frequent  conditions,  a  random
sample  of 1/97th  of  national  health  system  beneﬁciaries  has  been  built  since  2005,  called  the  échantillon
généraliste  des  bénéﬁciaires  (EGB).  The  aim  of  this  article  is  to describe  the  main  characteristics  of  the
SNIIR-AM  and  the EGB,  to detail  their  accessibility  according  to French  law,  and to present  their  strengths
and  limits.  It is  illustrated  with the  most  recent  studies  conducted  in  these  databases.  These  databases
include  demographic,  out-hospital  reimbursement  (including  drug  dispensing),  medical  (costly  long-
term diseases,  occupational  diseases,  sick-leaves.  . .), and  in-hospital  data.  All  these  data  are  prospectively
recorded,  individualized,  made  anonymous  and  linkable.  Consequently,  the  SNIIR-AM  is a very useful  data
source for  epidemiological,  pharmacoepidemiological  and  health  economics  studies,  particularly  for rare
diseases.  The  EGB  is appropriate  for long-term  research  on more  frequent  diseases.
©  2014  Société  nationale  française  de médecine  interne  (SNFMI).  Published  by  Elsevier  Masson  SAS.
All rights  reserved.
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Les  bases  de  données  de l’assurance  maladie  sont  collectées  depuis  2003  dans  un vaste  entrepôt
numérique,  le  Système  national  d’information  inter-régime  de  l’assurance  maladie  (SNIIR-AM).  La  résul-
tante en  est  une  des  plus  grandes  bases  médico-administratives  au  monde,  couvrant  65 millions  de
personnes.  Aﬁn  de  faciliter  l’étude  de  cohortes  de  patients  atteints  de  maladies  plus  fréquentes,  un
échantillon  au 1/97e des  assurés  à  l’assurance  maladie  a été  constitué  depuis  2005  : l’échantillon  général-nter-régime de l’assurance maladie
chantillon généraliste des bénéﬁciaires
iste  des  bénéﬁciaires  (EGB).  L’objectif  de cette  mise  au point  est  de présenter  les  grandes  lignes  de
l’architecture  du  SNIIR-AM  et  de  l’EGB,  leurs  modalités  d’accès,  leurs  intérêts  et leurs  limites.  Leur
édicale  est  illustré  par  les  publications  les  plus  récentes.  Ces  bases  de  donnéespotentiel  en  recherche  m
contiennent  des  données  démographiques,  les  données  de  remboursements  des  prestations  ambulatoires
(dont  les  délivrances  de  médicaments),  les données  médicales  des  régimes  de  l’assurance  maladie  (affec-
tions  de  longue  durée,  maladies  professionnelles,  arrêts  de  travail.  . .) et  les  données  hospitalières  issues
du programme  de  médicalisation  des  systèmes  d’information.  Toutes  ces  données  sont  individuelles,
 The French version of this article is available online (see Appendix A at the end of the text).
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prospectivement  recueillies,  anonymisées  et chaînables.  Tout  cela  fait du  SNIIR-AM  une source  de  données
très  intéressante  pour  la  recherche  épidémiologique,  pharmacoépidémiologique  et en  économie  de  la
santé,  particulièrement  pour  les  maladies  rares.  L’EGB  est  particulièrement  utile à  l’étude  des  maladies
plus  fréquentes  et  sur  le  long  terme.
© 2014  Société  nationale  française  de  médecine  interne  (SNFMI).  Publié  par  Elsevier  Masson  SAS. Tous
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cAs in North American and other European countries, French
ublic authorities want to develop the use of national medico-
dministrative databases for research. For that purpose, their
ccessibility to researchers is regularly improved [1–3]. This arti-
le is focused on the use of the French national health insurance
ystem databases for medical research.
The French universal health insurance system manages, through
ublic entities, all reimbursements of healthcare to all people
fﬁliated to a health insurance scheme in France. Accounts manage-
ent requires the generation of centralized databases, containing
lso administrative data. The result is one of the largest global
atabase of medical and administrative data in the general pop-
lation, covering nearly 65 million persons, far ahead of the
K’s Clinical Practice Research Datalink (approximately ﬁve mil-
ion persons), the Quebec Health Insurance Corporation (Régie de
’assurance maladie du Québec,  approximately four million per-
ons) or those of northern European countries [1]. Healthcare data
re collected prospectively at the local level, and then transmit-
ed to the National Health Insurance Fund for Salaried Workers
Caisse nationale de l’assurance maladie des travailleurs salariés
CNAMTS]) that hosts all the data in a huge digital warehouse
alled the National Health Insurance Inter-Scheme Information
ystem (Système national d’information inter-régime de l’assurance
aladie [SNIIR-AM]) [1,4]. All SNIIR-AM data are linkable: it is
ossible to identify and to link all data corresponding to a given
eneﬁciary among the dozen of tables contained in the SNIIR-
M.
Due to its width and to the individual, prospective and com-
lete data recording for all beneﬁciaries, the SNIIR-AM is a very
seful data source for medical research in the ﬁeld of epidemiol-
gy, pharmacoepidemiology and health economics of rare diseases.
o facilitate the building of patient cohorts for the most common
iseases, a sample of 1/97th of the SNIIR-AM has been established
ince 2005 in order to provide a 20-year follow-up of beneﬁciaries.
his sample is named the permanent beneﬁciaries sample (échan-
illon généraliste de bénéﬁciaires [EGB]) [4,5].
The aim of this article is to describe the main characteristics
f the SNIIR-AM and the EGB architectures, to present the condi-
ions for accessing to them and their main strengths and limitations
hen used for medical research. The potential of these databases
n medical research is illustrated by the most recent publications.
. Simpliﬁed architecture of the SNIIR-AM and the EGB
.1. The SNIIR-AM
The SNIIR-AM was created in 2003 following the 1999 social
ecurity funding law [6]. Its objectives are to improve the qual-
ty of healthcare, contribute to a better management of the Health
nsurance System and of public health politics, and inform health
ractitioners as regards their activity, accounts and prescriptions
7]. Initially consisting of only CNAMTS data (86% of insured
atients), it was gradually enriched in 2009 by the data of all
nsured patients by linkage with information of the programme for
he medicalization of information systems (programme de médi-
alisation des systèmes d’information [PMSI]) of public and privatedroits  réservés.
hospitals from 2007 to 2010, and by linkage with dates of death
(since 2009) [1].
Its general architecture and main recorded data are described in
Fig. 1.
The inter-scheme consumption data (données de consomma-
tion inter-régimes [DCIR]) set includes all outpatient reimbursed
health expenditures. These data are transmitted in real time by the
CNAMTS and the various special insurance schemes.
This DCIR database is also linked with data from the health insur-
ance medical service that includes information about long-term
diseases (LTD), occupational accidents, and occupational diseases.
PMSI data stem from all private or public hospitals and are pro-
vided to the CNAMTS for linkage to the SNIIR-AM. Information
includes the hospital identiﬁer, the dates of start and end of stays,
the diagnostic codes (one primary diagnosis, one related diagno-
sis and up to 30 associated diagnoses coded with the International
Classiﬁcation of Diseases, version ICD-10 [8]), the diagnosis-related
group (groupe homogène de malades [GHM]) coding, the proce-
dures (Classiﬁcation commune des actes médicaux [CCAM] coding),
the costly drugs dispensed, whether the stays occurred in a special
unit (resuscitation, intensive care, neonatology or palliative care),
and a score of severity for stays in intensive care units (Simpliﬁed
Acute Physiology Score II). A database exists for Medicine, Surgery
and Obstetrics hospitalisations (PMSI MCO  for médecine chirurgie
obstétrique), one for psychiatry (PMSI PSY for psychiatrie), one for
home hospitalisations (PMSI HAD for hospitalisaiton à domicile), and
one for after-care and rehabilitation (PMSI SSR for soins de suite et
de réadaptation). PMSI data are updated every three months [1,4].
Demographics (age, gender, place of residence – municipality
code, advantage of the Universal Health Coverage, afﬁliate scheme)
are available in the DCIR and PMSI databases.
Data of a given individual are linked through a unique identiﬁ-
cation number named numéro d’identiﬁcation au répertoire (NIR),
which is a unique identiﬁer for each insured person. However,
the NIR is not accessible in the SNIIR-AM in order to preserve the
identity of patients. It is made anonymous by a complex two-level
procedure called fonction d’occultation des informations nominatives
(FOIN), which is completely irreversible. This makes it difﬁcult to
match clinical cohort data with SNIIR-AM data (See Section 2) [1].
The depth of the SNIIR-AM is three years plus the current year.
PMSI data kept by the Technical Agency for Hospitalisation Infor-
mation (Agence technique d’information sur l’hospitalisation [ATIH])
have a sliding depth of 10 years plus the current year. The law allows
conservation of successive SNIIR-AM extractions corresponding to
10 years of follow-up [7].
1.2. The EGB
The EGB has been established in 2005. It is a sample of 1/97th
of insured persons in France, corresponding to 660,000 persons
[4,5]. It is built by a random selection of NIRs representative of
the French population by gender and by ﬁve-year increments [4].
The population of the EGB includes insured persons, whether they
are receiving healthcare or not. In contrast, only individuals receiv-
ing healthcare are present in the SNIIR-AM. All health insurance
schemes are included, except some special insurance schemes,
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Out-hospital reimbursements
Date, person who prescribes and who dispenses the care
For drugs: name, f
PMSI MCO, PSY, SSR, HAD
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SNIIR-AM (hosted by the CNAMTS )
Fig. 1. Simpliﬁed architecture of the French National Health Insurance Information System. CNAMTS: Caisse nationale de l’assurance Maladie des travailleurs salariés (National
Health Insurance Fund for Salaried Workers); DCIR: données de consommation inter-régimes (Inter-Scheme Consumption Data); HAD: hospitalisation à domicile (Home Hos-
pitalization); INSEE: Institut national des statistiques et des études économiques (National Institute of Statistics and Economic Studies); MCO: médecine, chriurgie, obstétrique
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dMedicine, Surgery, Obstetrics); PMSI: programme de médicalisation des systèmes d
NIIR-AM: Système national d’information inter-régime de l’assurance maladie (Nationa
nd  rehabilitation).
hose data are progressively implemented. Data available are
hose of the SNIIR-AM. They are also anonymous. Individual data
re stored and accessible for 20 years. When a patient dies, emi-
rates or is no longer insured, he or she is considered out of the
ohort: his/her data are retained but censored on the release date.
ewly insured persons are added quarterly to the EGB to keep con-
tant the proportion of 1/97th of the insured persons in France
4].
Table 1 compares the SNIIR-AM with EGB. Because of the depth
f the database and accessibility, the EGB is a database of choice for
ong-term cohorts of patients with common diseases.
. Conditions for accessing the SNIIR-AM and the EGB
Conditions for accessing the SNIIR-AM and the EGB are strictly
egulated by law [7]. The Health Data Institute (Institut des données
e santé [IDS]) ensures the consistency of medico-administrative
atabases, data quality and availability of databases for research
9]. Any access request to the SNIIR-AM or the EGB for a project
equires authorization from the IDS. Only non-proﬁt research can
pply [10].
Access to the EGB requires a direct secured connection to a
evoted server, with no possibility to import data. As there is no
atabase creation, only authorization from the IDS is required.ation (Program for the Medicalization of Information Systems); PSY: psychiatry;
th Insurance Information System); SSR: services de suite et de réadaptation (after-care
Direct access to the SNIIR-AM is not possible. Following autho-
rization from the IDS and the National Data Protection Commission
(Commission nationale de l’informatique et des libertés [CNIL]),
CNAMTS engineers extract from the SNIR-AM the study popula-
tion according to the inclusion and non-inclusion criteria given to
them. Data are supplied on a secure, electronic medium.
As noted above, SNIIR-AM and EGB data are irreversibly anony-
mous. Collecting the patients’ NIR in a clinical cohort (in order to
link cohort data with SNIIR-AM data) currently requires a State
Council (Conseil d’État)  decree, making this an almost impossible
strategy in practice. A second strategy is to identify the NIRs achiev-
ing a probabilistic matching. It consists in recording in the clinical
cohort indirect identifying data (date and place of birth, gender),
plus possibly directly identifying data (name and surname). Then,
these data are searched in the NIR repertory in order to try to iden-
tify the NIR that corresponds to a given patient. However, this later
strategy can lead to errors and non-completeness in NIR identiﬁ-
cation [1].3. Advantages and limitations
The advantages and limitations of the SNIIR-AM and of the
EGB with existing or planned solutions to the limitations are
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Table 1
Comparison of the Système national d’information inter-régime de l’assurance maladie (SNIIR-AM) to the échantillon généraliste des bénéﬁciaires (EGB).
SNIIR-AM EGB
Population All insurance schemes (since 2009)
Only individuals receiving reimbursed healthcare (patients)
Dynamic sample of 1/97th (n = 660,000) of insured persons in France
except SLM and some rare insurance schemes (not necessarily ill)
Beneﬁting from health care or not
Rare problem of loss of follow-up
Database depth 3 years + the current year; 10 years for the PMSI
Possibility to stock data for 10 years
Recording during 20 years (start in 2005)
Data  Out-hospital reimbursed healthcare
ALD, work accidents, occupational diseases, sick-leaves
PMSI MCO, PSY, HAD, SSR
Out-hospital reimbursed health cares
ALD, work accidents, occupational diseases, sick-leaves
PMSI MCO  only
Access Non-proﬁt research organizations
IDS authorization
CNIL authorization
Extraction by CNAMTS engineers
Non-proﬁt research organizations
IDS authorization
Direct access by connection to EGB server
Preferential use Studies on rare diseases Diseases with high prevalence
Studies needing rapid results
ALD: affection de longue durée (long-term disease); CNAMTS: Caisse nationale de l’assurance maladie des travailleurs salariés (National Health Insurance Fund for Salaried
Workers); CNIL: Commission nationale de l’informatique et des libertés (National Data Protection Commission); EGB: échantillon généraliste des bénéﬁciaires (permanent
b stitut
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ieneﬁciaries sample); HAD: hospitalisation à domicile (home hospitalization); IDS: in
ystèmes d’information (Program for the Medicalization of Information Systems); PS
nter-régime de l’assurance maladie; SSR: soins de suite et de réadaptation (after-care 
ummarized in Table 2. The main uses of these databases for med-
cal research are listed in Table 3.
The main limitation of these databases is their complexity.
n extraction of the SNIIR-AM has several dozen of tables, some
nly used for accountancy, containing hundreds of variables and
able 2
dvantages and limitations of the SNIIR-AM and the EGB.
Advantages Limita
Architecture Overall sight of the patient’s care
program
Financial data (health economics
studies)
Prospective recording of the data
Depth of the database: 2005-2025
(EGB)
Compl
Time-v
year (S
Insured persons All insured persons in France,
healthcare consumption in a
“real-world” practice
Compl
childre
severa
No det
Absen
Out-hospital healthcare data Date and price of the health care,
identity of the prescriber and of the
dispenser
Drugs: date, exact pharmaceutical
form, number of dispensed units
No rec
No rec
paracl
Drugs:
record
not rec
In-hospital data All hospital stays in public or
private hospitals in France
Up to 32 diagnosis codes,
procedures, costly drug dispensing,
hospitalization in special care
departments (intensive care units,
neonatology. . .)
Isolate
not rel
No det
exposu
treatm
PMSI P
featur
from t
No  dat
housin
No dat
proced
Access Easy  individual access to the EGB
server
17 mo
SNIIR-
No  dir
NAV: Caisse nationale d’assurance vieillesse (National Fund for Ageing); EGB: échantillon 
 domicile (home hospitalization); NIR: numéro d’inscription au répertoire (unique iden
ystèmes d’information (Program for the Medicalization of Information Systems); PSY: psy
nter-régime de l’assurance maladie; SSR: soins de suite et de réadaptation (after-care and re des données de santé (Health Data Institute); PMSI: programme de médicalisation des
chiatry; SLM: sections locales mutualistes; SNIIR-AM: Système national d’information
habilitation).
millions of lines. A SNIIR-AM dictionary is available for users of
the health insurance databases. As the EGB is dedicated to medi-
cal research, a “simpliﬁed EGB” emerged in late 2013, simplifying
the presentation of outpatient healthcares. However, training on
the complex architecture of these bases is mandatory since 2013.
tions Recent proposal for improvement
exity, constant evolution Training by the CNAMTS and the IDS
(currently available)
Creation of the “simpliﬁed EGB”
(end-2013)
arying depth of 3 years + current
NIIR-AM)
Increase of SNIIR-AM depth and
possibility to stock consecutive
extractions
exity to identify healthcare for
n due to the possibility of
l rights holder
Creation of a national health identiﬁer
ailed socio-professional data Linkage with CNAV data
ce of the SLM in the EGB Addition to SLM data currently
implemented in the EGB
ording of the indications
ording of the results of
inical examinations
 prescription data are not
ed; over-the-counter drugs are
orded
Pharmacoepidemiological approaches
for modelization of drug exposure
d diagnosis codes sometimes
iable
ailed clinical data; no drug
re data excepted costly
ents
Algorithms combining LTD and
hospitalization diagnosis codes,
procedures and drugs
SY, HAD and SSR poorly
ed in the SNIIR-AM and absent
he EGB
Improvement of PMSI PSY, HAD and
SSR encoding; PMSI PSY, HAD et SSR
currently implemented in the EGB
a from medico-social structures
g ageing people
Addition of data from medico-social
structures for ageing people (currently
tested)
a for consultation if no
ure is performed
Coding of consultations
nths on average to obtain
AM extraction
Improvement of accessibility to
SNIIR-AM data
ect access to the NIR Drafting by the State Council of a
decree serving as general framework
for secure access to the NIR
généraliste des bénéﬁciaires (permanent beneﬁciaries sample); HAD: hospitalisation
tiﬁcation number for any insured adult); PMSI: programme de médicalisation des
chiatry; SLM: sections locales mutualistes; SNIIR-AM: Système national d’information
habilitation).
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Table  3
Main uses of the French health insurance system databases for medical research.
Field Main uses
Epidemiology Assessment of incidence and prevalence of
diseases
Assessment of geographical variations of
incidence and prevalence of
diseases–description of healthcare programs
(procedures, examinations performed for a
given disease)
Assessment of the impact of guidelines on
healthcare
Pharmacoepidemiology Assessment of vaccine coverage
Quantiﬁcation of drug exposure
Assessment of rare adverse drug events
Assessment of drug effectiveness in the
world-life practice, including comparisons not
carried out in trials before marketing
Assessment of the impact of health decision or
campaign on drug consumption
Health economics Assessment of healthcare costs (procedures,
examinations, work stoppage, sick-leaves,
transport. . .)
Cost-effectiveness comparisons of therapeutic
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aor prevention strategies
he EGB and the SNIIR-AM user groups meet regularly with ofﬁ-
ials of the IDS and the CNAMTS to keep abreast of updates, and
ommunicate on secure forums. The EMOIS (évaluation, manage-
ent, organisation, information, santé) group organizes meetings
nd publishes reports to promote and improve research on the
NIIR-AM and the EGB [11]. Working on these data also requires
ufﬁcient knowledge of data management using the statistical soft-
are SASTM (SAS Institute, North Carolina, USA) used on the EGB
erver. Working on SNIIR-AM data extractions requires to have a
ecured server with sufﬁcient capacity.
As previously suggested, a second general limitation is the
ccess to SNIIR-AM data extractions. Obtaining the necessary
uthorizations and data extraction by CNAMTS engineers requires
7 months on average [10].
.1. Advantages and limitations in epidemiology
The major advantage of these databases is the huge number of
atients they include and the prospective data collection. There-
ore, large cohorts can be built in these databases to clarify the
pidemiology of diseases at a nationwide level and taking into
ccount geographical variations. The SNIIR-AM is a very useful
ata source to estimate the incidence and prevalence of rare dis-
ases, such as lupus or immune thrombocytopenia [12,13]. For
nstance, we could identify 3771 incident immune thrombocy-
openia patients in the SNIIR-AM during a two-year period [13].
or comparison, the most important cohort of immune thrombo-
ytopenia patients ever built in medico-administrative databases
as in the UK Clinical Practice Research Datalink that identiﬁed
145 incident adults during a 15-year period. The huge number of
atients followed in the SNIIR-AM allows the assessment of varia-
ions according to age, gender, seasons or areas [12,13].
A possible limitation in the use of medico-administrative
atabases in epidemiology is the validity of diagnosis codes. Quality
ontrol before data transmission to the CNAMTS and audits involves
ainly the treatment of aberrant or missing data [4]. Moreover,
nancial coding of healthcare is preferentially checked. LTD attri-
utions are not exhaustive for a given disease: for example, patients
ho have already obtained a LTD for diabetes mellitus and suffer-
ng from myocardial infarction do not systematically request for
 new LTD for myocardial infarction [1]. In the PMSI, the details ofe interne 36 (2015) 411–417 415
diagnosis codes (primary, related and associated) should be studied
and not the GHMs, which form an accounting harmonization. Lim-
itations in the accuracy of coding are inherent to those of the
ICD-10 [8]. Consequently, several French researchers and CNAMTS
engineers develop algorithms for the identiﬁcation of prevalent
or incident patients that combine LTD and PMSI diagnosis codes,
medical procedures and drugs used as proxies (such as antidiabetic
or hypoglycaemic drugs to identify diabetic patients). Recently, an
approach combining diagnosis codes, endoscopic and surgical pro-
cedures demonstrated its efﬁcacy in identifying incident patients
with colonic cancer [14]. Similarly, an estimation method of the
Charlson comorbidity score, an important covariable in epidemi-
ology, has been validated in the SNIIR-AM [15]. It uses similar
algorithms to identify comorbidities.
A second limitation is the lack of detailed clinical data and of
results of paraclinical examinations. Only events accompanying the
diagnosis or complicating the disease are encoded in the PMSI. The
inability to collect the NIR prevents any reliable connection with
clinical data. Recent reports of the High Council of Public Health
(Haut Conseil de la Santé Publique) [1] and Bras-Loth report com-
missioned by the Minister of Social Affairs and Health [2] stress
the urgency of drafting a State Council decree serving as a general
framework for secured access to the NIR.
Moreover, the PMSI database does not collect the entire hospital
activities: in the absence of procedure, consultations and emer-
gency department stays lasting less than 24 hours are not recorded.
The PMSI PSY, SSR and HAD are still poorly featured in the SNIIR-AM
and absent from the EGB.
Patients are identiﬁed thanks to their NIR. That makes studies
carried out in pediatric populations more complex. Indeed, children
do not have their own rights as insured persons. Consumption of
care is through their “rights holder” (usually the legally guardian).
As a child may  have several rights holders (both parents, for exam-
ple) to facilitate access to care, the consumption of care of one
child can be linked in the SNIIR-AM with several identiﬁers. A
national health identiﬁer should soon be created to solve this prob-
lem [1].
Lastly, demographic data are limited. Only all-cause mortality
can now be evaluated in the SNIIR-AM as in a recent follow-up
study in the general population after initial hospitalisation for
heart failure [16]. The causes of death should be speciﬁed in the
SNIIR-AM in the near future by individual linkage of the causes
of death from the epidemiology centre for causes of death (Centre
d’épidémiologie des causes de décès [CépiDc]) of the National Insti-
tute of Health and Medical Research (Institut national de la santé et
de la recherche médicale [Inserm]) [1]. Lack of socio-professional
data could be completed in the future by linkage of data with
the National Fund for Ageing (Caisse nationale de vieillesse) [1]. A
score of social deprivation [17] may  also soon be added in the
EGB.
3.2. Advantages and limitations in pharmacoepidemiology
The ﬁeld of pharmacoepidemiology assesses the use, the effec-
tiveness and the safety of drugs in a real-world practice (after
marketing authorization). Therefore, health insurance databases
are frequently used as a material for pharmacoepidemiological
studies. They are the most appropriate tools to evaluate the immun-
isation coverage in the general population [18,19] or speciﬁc
populations. We  have estimated the exposure to pneumococcal
vaccine in adult patients with primary immune thrombocytopenia
treated with rituximab [20] as recommended by French guidelines
[21]. The EGB was also used to assess the relative frequency of pre-
scribing biotherapies in rheumatoid arthritis [22]. Health insurance
databases are tools of choice to assess compliance with the rec-
ommendations at the population level, as shown recently by the
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xposure to recommended drugs after myocardial infarction [23].
owever, they cannot be used to assess accurately the reasons for
on-adherence to recommendations.
The depth of the EGB make possible a dynamic view of drug
xposure: our team was able to show the increasing number of
atients exposed to baclofen in recent years for alcohol abuse
24] and the impact of health authorities alerts about safety of
ntipsychotics in elderly patients on the rate of prescription of psy-
hotropic drugs in this population [25]. Moreover, the SNIIR-AM
nd the EGB allow the identiﬁcation of consumer proﬁles [26].
Drug effectiveness in real-world practice can be assessed from
he SNIIR-AM or the EGB, by overall mortality (soon, cause-speciﬁc
ortality), and serious events (in-hospital and LTD diagnosis codes,
rocedures or drugs used as proxies). These databases are a pow-
rful material to compare the efﬁcacy of two drugs with the same
ndication, but which have not been compared in clinical trials.
oreover, they allow stratiﬁcation of the analyses on subgroups
f patients excluded from clinical trials (elderly patients with
omorbidities, poly-medicated, etc.) due to the large number of
atients they include. Recently, a study conducted in the SNIIR-AM
nd including 163,801 patients showed no superiority of rosuvas-
atin compared with simvastatin used for primary prevention in
educing mortality and the occurrence of stroke and myocardial
nfarction [27].
The SNIIR-AM and the EGB are particularly suitable bases for
ost-marketing authorization safety studies, in order to assess
he occurrence of rare adverse events [28–30]. Such studies have
reviously led to decisions of public health as regards drug market-
ng. Of note, these safety studies in the SNIIR-AM are not limited
o drugs: a study assessing the impact of complications after
olonoscopy (such as perforation and gastrointestinal bleeding)
as been recently published [31]. As regards immunopathology,
hese databases are appropriate for the follow-up in the long-term
f cohorts of patients suffering from rare diseases. Two studies
arried out in a Canadian database similar to the SNIIR-AM (the
égie de l’assurance maladie du Québec database) assessed the risk of
nfection on corticosteroids in older rheumatoid arthritis patients
32,33]. Our team is currently working in the SNIIR-AM with a
imilar approach on the beneﬁt-to-risk balance of the different
herapeutic strategies used in primary immune thrombocytopenia
FAITH study, No. ENCePP 4574) [34]. Lastly, in-hospital and out-
ospital ﬁnancial data are extremely detailed, and research in
he ﬁeld of health economics is rising in the SNIIR-AM and the
GB.
However, some limitations should be kept in mind: as men-
ioned previously, the indications of treatments and of paraclinical
xaminations are not recorded. They are deducted from LTD and
ospital diagnosis codes, as well as from some procedures or drugs
sed as proxies. Only dispensing of reimbursed drugs is recorded:
elf-medication with over-the-counter drugs cannot be measured.
etailed information regarding the dose of pharmaceutical forms
nd the number of units dispensed are available. However, the
rescribed dose is not recorded. This should be modelized thanks
o pharmacoepidemiological methods. These approaches use most
requently the Deﬁned Daily Dose deﬁned for each drug by the
orld Health Organization [35]. Validation of these pharmacoepi-
emiological methods is an important ﬁeld of research, for instance
egarding the modelization of drug exposure from rare dispensing
36] or the impact of cumulative doses [37]. During hospital stays,
nly data regarding the dispensed costly drugs are available. There-
ore, it is difﬁcult to identify an exposure to cyclophosphamide
or instance. Current generalization of computerized prescription
n French hospitals may  ﬁll this “black hole” of in-hospital drug
xposures. Lastly, let recall that dispensing is not synonymous of
rug intake by patients, but this is a pitfall of most studies on
rugs.
[ne interne 36 (2015) 411–417
4. Conclusion
The SNIRR-AM and the EGB offer great possibilities for medical
research, particularly in Internal Medicine: allowing the building
of cohorts with prospective recording of data and with unequaled
statistical power, they might contribute to better know the epi-
demiology of rare diseases, and may  have an impact on guidelines
for their treatment. A major issue remains the facilitation of data
linkage with the data of clinical cohorts.
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